Trial Profile

A PHASE 1, OPEN-LABEL, DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND ANTI TUMOR ACTIVITY OF PF-07799933 (ARRY-440) AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 16 YEARS AND OLDER WITH ADVANCED SOLID TUMORS WITH BRAF ALTERATIONS

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 27 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Binimetinib (Primary) ; Cetuximab (Primary) ; PF-07799933 (Primary)
Indications Brain cancer; Colorectal cancer; Malignant melanoma; Solid tumours
Focus Adverse reactions; First in man; Therapeutic Use
Sponsors Pfizer

20 May 2025 Planned End Date changed from 9 Aug 2028 to 28 Sep 2028.
20 May 2025 Planned primary completion date changed from 6 Feb 2027 to 28 Mar 2027.
12 Mar 2025 Planned End Date changed from 23 Mar 2028 to 9 Aug 2028.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com